Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Meta-Analysis In Lancet Projects End of Beta-Blockers For Hypertension

Executive Summary

Beta-blockers should not remain the first-line therapy for high blood pressure, researchers of a study published in the Oct. 18 Lancet said

You may also be interested in...



Merck Cozaar Will Get Stroke Risk Reduction Claim – FDA’s Temple

Merck Cozaar data from the LIFE study support a risk reduction claim for strokes rather than a broader new indication, FDA Office of Medical Policy Director Robert Temple, MD, said

Antihypertensive Outcomes Labeling Emphasized By FDA After ALLHAT

FDA is planning to include clinical outcomes data in antihypertensive labeling in light of findings from the ALLHAT and LIFE studies

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

Topics

UsernamePublicRestriction

Register

PS046470

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel